contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-vigtig-milepael-for-rnx-011

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Pharma Equity Group

Selskabets datterselskab Reponex har modtaget myndighedsgodkendelse til at igangsætte et afgørende fase-2 studie med lægemiddelkandidaten RNX-011 til behandling af sekundær peritonitis - en livstruende intra-abdominal infektion med høj dødelighed.

Selskabets datterselskab Reponex har modtaget myndighedsgodkendelse til at igangs&#xe6;tte et afg&#xf8;rende fase-2 studie med l&#xe6;gemiddelkandidaten RNX-011 til behandling af sekund&#xe6;r peritonitis - en livstruende intra-abdominal infektion med h&#xf8;j d&#xf8;delighed.
<ul>
<li>Studiet er randomiseret, placebokontrolleret fors&#xf8;g, hvor en unik triple-therapy(fosfomycin, metronidazol ogGM-CSF) gives direkte i bughulen under operation</li>
<li>Prim&#xe6;rt endpoint: Reduktion af alvorlige postoperative komplikationer(fx. abscesser og re-operationer) - et v&#xe6;rdiskabende m&#xe5;l for potentielle licenspartnere</li>
<li>Ydekiger endpoints: Lokal inflammation (IL-6) samt patienters restitution (QoR-15)</li>
<li>F&#xf8;rste patient forventes inkluderet i Q4-2025 - totalt skal 32 patienter indrulles i studiet.</li>
</ul>
CEO Christian Tange udtaler - &quot;Godkendelsen er en afg&#xf8;rende kommerciel milep&#xe6;l. Vi bev&#xe6;ger os nu fra proof-of-concept til et studie designet til at levere de data, store farmaselskaber eftersp&#xf8;rger &#x2013; med m&#xe5;let om fundamentalt at forbedre behandlingen for en meget s&#xe5;rbar patientgruppe&quot;.&#xa0;
L&#xe6;s hele meddelelsen her: <a href="https://pharmaequitygroup.com/news-and-press/" target="_blank" rel="noopener">Reponex - RNX-011</a>
Disclaimer: HC Andersen Capital modtager betaling fra Pharma Equity Group for en Digital IR-abonnementsaftale./Claus Thestrup 01.09.2025, kl. 15:00.

HC Andersen Capital

<ul>
<li>Reponex, et datterselskab af Pharma Equity Group, har modtaget myndighedsgodkendelse til at starte et fase-2 studie med lægemiddelkandidaten RNX-011 til behandling af sekundær peritonitis.</li>
<li>Studiet er et randomiseret, placebokontrolleret forsøg, der fokuserer på at reducere alvorlige postoperative komplikationer, hvilket er et værdiskabende mål for potentielle licenspartnere.</li>
<li>CEO Christian Tange betragter godkendelsen som en afgørende kommerciel milepæl, der markerer overgangen fra proof-of-concept til et studie, der kan levere data efterspurgt af store farmaselskaber.</li>
</ul>Dette indhold er genereret af AI. Du kan give feedback om det på Inderes <a href="https://forum.inderes.com/t/inderes-fi-sisallon-kehitysideat/71/last">forum</a>.

Pharma Equity Group: Vigtig milepæl for RNX-011

Summary